Myeloma protein
|
WikiDoc Resources for Myeloma protein |
|
Articles |
|---|
|
Most recent articles on Myeloma protein Most cited articles on Myeloma protein |
|
Media |
|
Powerpoint slides on Myeloma protein |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Myeloma protein at Clinical Trials.gov Trial results on Myeloma protein Clinical Trials on Myeloma protein at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Myeloma protein NICE Guidance on Myeloma protein
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Myeloma protein Discussion groups on Myeloma protein Patient Handouts on Myeloma protein Directions to Hospitals Treating Myeloma protein Risk calculators and risk factors for Myeloma protein
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Myeloma protein |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Myeloma Protein is usually a monoclonal antibody or immunoglobulin fragment that is produced by malignant myeloma cells, or plasma cells.
Other terms for this protein is M-protein, spike protein,or paraprotein. This proliferation of the myeloma protein has several deleterious effects on the body, including impaired immune function, abnormally high viscosity ("thickness") of the blood, and kidney damage.[1]